{"id":48025,"date":"2022-09-06T20:01:40","date_gmt":"2022-09-06T18:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-exosome-market-report-2022-rising-numbers-of-clinical-trials-propelling-sector-forward-researchandmarkets-com\/"},"modified":"2022-09-06T20:01:40","modified_gmt":"2022-09-06T18:01:40","slug":"global-exosome-market-report-2022-rising-numbers-of-clinical-trials-propelling-sector-forward-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-exosome-market-report-2022-rising-numbers-of-clinical-trials-propelling-sector-forward-researchandmarkets-com\/","title":{"rendered":"Global Exosome Market Report 2022: Rising Numbers of Clinical Trials Propelling Sector Forward – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “The Global Exosome Market – Market Size, Forecast, Trials, and Trends, 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nExosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.\n<\/p>\n

\nThe cargo contained within exosomes can offer prognostic information for a range of diseases – including cardiovascular, renal, neurodegenerative, and metabolic diseases – as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.\n<\/p>\n

\nImportantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a specific course of treatment.\n<\/p>\n

\nExosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.\n<\/p>\n

\nThe Era of Exosomes<\/strong>\n<\/p>\n

\nFor these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.\n<\/p>\n

\nTo date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.\n<\/p>\n

\nToday the exosome industry is witnessing:<\/strong>\n<\/p>\n